Upstream Bio Details Phase 3 Plans for Verekitug in Asthma and CRSwNP Treatment
Upstream Bio, Inc. has unveiled its pivotal Phase 3 development strategy for verekitug, a drug candidate aimed at treating severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This advancement signifies a crucial step in bringing a potential new therapeutic option to patients suffering from these chronic respiratory conditions.